Clinical Trial

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-09-24; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2026-02-16
Trial Details
NCT Number NCT07197671
Lead Sponsor University of Wisconsin, Madison
Collaborators: Archeus Technologies, Inc., National Cancer Institute (NCI)
Conditions Metastatic Cancer
Enrollment 60 participants
Start Date 2026-11-01
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-23